China Thrombosis Treatment Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the China Thrombosis Treatment Market was valued at USD 508.0 million in 2025 and is projected to reach USD 831.88 million by 2032, growing at a CAGR of approximately 7.3% during 2026–2032.
China Thrombosis Treatment Market Highlights
| Report Metric | Details |
| Report Name | China Thrombosis Treatment Market |
| Market Size 2025 | USD 508.0 million |
| Market Size 2032 | USD 831.88 million |
| Absolute Growth 2025–2032 | USD 323.88 million |
| CAGR 2026–2032 | 7.3% |
| Peak Annual Growth | 9.3% in 2030 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Treatment Type, 2025 | Pharmacologic Therapy (53% share) |
| Leading Patient Category, 2025 | Elderly Patients (46% share) |
| Leading Delivery Setting, 2025 | Inpatient (41% share) |
| Leading End User, 2025 | Hospitals (42% share) |
| Fastest-Growing Treatment Type | Catheter-Directed Therapy (9.9% CAGR) |
| Fastest-Growing Patient Category | Chronic Cases (9.0% CAGR) |
| Fastest-Growing Delivery Setting | Cath Lab (8.6% CAGR) |
| Fastest-Growing End User | Surgical Centers (8.4% CAGR) |
| Growing Sector | Surgical Centers |
| Key End Users | Hospitals, Surgical Centers, Long-Term Care Units, Interventional Radiology |
China Thrombosis Treatment Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
Year by year, the estimates below pair each growth rate with the development that shaped it.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 5.8 | The market experienced steady growth, reflecting ongoing demand for thrombosis treatments driven by the 'Thrombosis Awareness Campaign'. |
| 2023 | 8.4 | A rise in thrombosis cases among the elderly contributed to accelerated market growth, as reported by the National Health Commission. |
| 2024 | 5.6 | Growth slowed as hospitals faced challenges in managing increased patient volumes due to rising chronic disease prevalence. |
| 2025 | 7.8 | Demand surged due to improved treatment protocols and increased hospital admissions for cardiovascular diseases. |
| 2026 | 7.0 | A slight slowdown occurred as the market is expected to adjust to new treatment standards introduced by the Ministry of Health. |
| 2027 | 7.5 | Growth is projected to resume as hospitals expand their thrombosis management capabilities, improving treatment accessibility for patients. |
| 2028 | 5.5 | Market growth is expected to slow again as treatment accessibility becomes a concern for patients in rural areas. |
| 2029 | 6.7 | An increase in thrombosis-related consultations is projected to boost market performance, indicating heightened awareness among healthcare providers. |
| 2030 | 9.3 | The peak growth rate is expected to be driven by heightened awareness and treatment accessibility due to public health initiatives. |
| 2031 | 7.9 | Growth is anticipated to decelerate as hospitals adjust to evolving patient needs and increasing demands for specialized care. |
| 2032 | 7.2 | The market will continue to grow as chronic disease prevalence rises, necessitating more thrombosis treatment options. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
China Thrombosis Treatment Market Synopsis
Thrombosis Treatment in China encompasses medical interventions designed to manage blood clots, including pharmacologic therapies and surgical procedures. With an average patient age of 65 years, the demand for effective treatments is clear. The China Thrombosis Treatment Market is growing, driven by an increasing elderly population and a rising prevalence of chronic diseases. In 2023, the government allocated 1 billion CNY for cardiovascular disease research, further stimulating demand. Improved treatment protocols and a rise in hospital admissions are key contributors to this growth.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Growing elderly population | Driver | High | Elderly Patients |
| Increased prevalence of chronic diseases | Driver | High | Chronic Cases |
| Rising demand for specialized treatment facilities | Opportunity | High | Surgical Centers |
| Expansion of thrombosis management programs | Opportunity | Medium | Long-Term Care Units |
| Limited accessibility to advanced treatments | Restraint | High | Pharmacologic Therapy |
| High costs associated with surgical procedures | Restraint | Medium | Surgical Thrombectomy |
| Inadequate training for healthcare providers | Challenge | High | Interventional Radiology |
| Delays in patient diagnosis and treatment initiation | Challenge | Medium | Cath Lab |
Evaluation of Drivers in China Thrombosis Treatment Market (2026–2032)
The factors lifting demand, and the evidence behind each, are summarised below.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Increased hospital admissions for cardiovascular diseases | Inpatient | In 2022, approximately 11 million hospital admissions for cardiovascular diseases boosted demand for thrombosis treatment. |
| Growing awareness of thrombosis management | Elderly Patients | The 'Thrombosis Awareness Campaign' launched in 2021 has educated the public, increasing treatment demand. |
| Investment in specialized surgical centers | Surgical Centers | Urban surgical centers reported a 20% increase in thrombectomy procedures since 2020, reflecting rising demand. |
| Integration of thrombosis management in long-term care | Long-Term Care Units | Long-term care units have increasingly adopted thrombosis management programs since 2021 to improve patient outcomes. |
| Guidelines for catheter-directed therapies | Catheter-Directed Therapy | The Chinese Society of Interventional Radiology published guidelines in 2022, promoting targeted treatment options. |
Market growth for Thrombosis Treatment in China is underpinned by increased hospital admissions for cardiovascular diseases, with approximately 11 million cases reported in 2022. The rise in thrombectomy procedures, which have increased by 20% since 2020, indicates a shift towards specialized care. The publication of guidelines for catheter-directed therapies in 2022 has encouraged the adoption of advanced treatment options, improving overall patient care. Increased awareness from public health campaigns has further driven demand for effective thrombosis management solutions.
Evaluation of Restraints in China Thrombosis Treatment Market
The table below lists the restraints and the evidence behind each.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Limited accessibility to advanced treatments | Pharmacologic Therapy | Many patients face barriers accessing advanced thrombosis treatments due to geographical and financial constraints. |
| High costs associated with surgical procedures | Surgical Thrombectomy | The average cost of surgical thrombectomy is 15,000 CNY, which can deter patients from seeking necessary care. |
| Inadequate training for healthcare providers | Interventional Radiology | A lack of specialized training for healthcare providers limits the effective implementation of thrombosis treatments. |
| Delays in patient diagnosis and treatment initiation | Cath Lab | Patients often experience delays in diagnosis, leading to complications and reduced treatment efficacy. |
| Insufficient public awareness of thrombosis risks | Elderly Patients | Despite campaigns, many elderly patients remain unaware of thrombosis risks, hindering timely treatment. |
China Thrombosis Treatment Market Challenges
Buyers and suppliers in the China thrombosis treatment market are grappling with a critical skills shortage, as many surgical centres struggle to recruit qualified personnel for complex procedures. This shortage stems from inadequate training programs, resulting in longer wait times for patients needing urgent care. The average cost of surgical thrombectomy procedures, at 15,000 CNY, can deter patients from pursuing necessary treatment options. Heightened competition among healthcare facilities has led to aggressive pricing strategies that may compromise treatment quality, posing challenges for buyers seeking effective solutions. Compliance with ISO 9001 standards complicates the implementation of new treatment protocols in hospitals, causing further delays in patient care.
Trends in the China Thrombosis Treatment Market
The trends below show where the China Thrombosis Treatment Market is heading.
- Shift towards Integrated Thrombosis Management in Hospitals: Major hospitals in urban areas are increasingly adopting integrated thrombosis management programs. In 2023, the cardiology department reported a 30% rise in thrombosis-related consultations, indicating a growing focus on comprehensive treatment.
- Increased Adoption of Catheter-Directed Therapies: The introduction of guidelines for catheter-directed therapies in 2022 has led to a surge in their adoption. Surgical centres have reported an 8.6% growth in catheter-based treatments, reflecting the shift towards targeted interventions.
- Growing Emphasis on Elderly Health Initiatives: The Ministry of Health's 'Elderly Health Initiative' launched in 2020 has focused on thrombosis prevention and treatment. This initiative aims to reduce cardiovascular disease incidence by 20% by 2030, highlighting the importance of addressing elderly health.
- Expansion of Thrombosis Awareness Campaigns: The 'Thrombosis Awareness Campaign' launched in 2021 has increased public knowledge about thrombosis. This initiative has contributed to a 15% increase in thrombosis cases reported among the elderly in 2023.
Investment Opportunities in the China Thrombosis Treatment Market
Investors looking at the China Thrombosis Treatment Market should consider the following areas.
- Collaborative Efforts with Surgical Centers: With a 20% increase in thrombectomy procedures, surgical centres present an opportunity for collaboration. Establishing partnerships can improve treatment accessibility for patients in urban areas, enhancing care outcomes.
- Investment in Long-Term Care Units: The growing integration of thrombosis management programs in long-term care units indicates a need for investment. Targeting these facilities can improve patient outcomes for chronic cases, addressing a significant market gap.
- Standardization of Thrombosis Treatment Protocols: The publication of guidelines for catheter-directed therapies presents an opportunity to develop standardised treatment protocols. Engaging with hospitals can facilitate the adoption of these protocols, ensuring consistent care.
- Raising Public Awareness: The increasing prevalence of chronic diseases, projected to reach 50% by 2030, creates a gap for awareness campaigns. Investing in educational initiatives can drive demand for thrombosis treatment, benefiting the overall healthcare system.
Government Initiatives in the China Thrombosis Treatment Market
In 2022, the Ministry of Health approved the 'Thrombosis Management Strategy', which improves treatment protocols in hospitals. This measure complements the 'Cardiovascular Disease Prevention and Control Plan' launched in 2021, aimed at improving access to thrombosis treatments. Together, these initiatives focus on raising awareness and improving healthcare infrastructure to better manage thrombosis cases, ultimately benefiting patients and providers alike.
In 2023, the Chinese government allocated 1 billion CNY for cardiovascular disease research, administered by the National Health Commission. This funding supports various initiatives, including the development of new treatment protocols and public awareness campaigns. The 'National Cardiovascular Disease Surveillance Program' was updated to include thrombosis as a key focus area, ensuring ongoing monitoring and improvement of treatment standards.
Future Insight of the China Thrombosis Treatment Market
The thrombosis treatment market in China is expected to develop substantially by 2032, driven by increased government investment in cardiovascular disease research and public education campaigns. The introduction of updated treatment guidelines by medical associations will standardise practices and improve patient outcomes. By 2030, as chronic disease prevalence rises to 50%, healthcare providers will likely expand their thrombosis management programs to accommodate growing patient needs. The government's subsidy for thrombolytic drugs will enhance access to treatments, allowing more patients to receive timely interventions.
Market Segmentation Analysis
Each segment group is reviewed below, with the leader by share and the fastest grower by CAGR.
By Treatment Type – Pharmacologic Therapy Dominated, Catheter-Directed Therapy Expected to Grow Fastest
According to Vasudha, AM at 6Wresearch, Pharmacologic Therapy accounted for a 53% market share by treatment type in 2025. Pharmacologic therapy holds the largest share in the China thrombosis treatment market due to its essential role in effectively managing blood clots. This treatment is particularly crucial for the elderly population, which has seen a 15% increase in thrombosis cases in 2023. Catheter-Directed Therapy is projected to grow fastest, at a CAGR of 9.9% during 2026–2032. Catheter-directed therapy is experiencing rapid growth, driven by a 20% increase in thrombectomy procedures reported in urban surgical centers since 2020. This method's ability to precisely target specific clot locations enhances its appeal among healthcare providers and patients. Suppliers should focus on ensuring the availability of pharmacologic therapies while also investing in catheter-directed technologies to meet the rising demand.
By Patient Category – Elderly Patients Dominated, Chronic Cases Expected to Grow Fastest
With a 46% revenue share in 2025, Elderly Patients was the largest patient category category. Elderly patients represent the largest share of the thrombosis treatment market in China, largely due to their higher incidence of thrombosis. With the average age of thrombosis patients being 65 years, this demographic is critical for treatment strategies and healthcare planning. The quickest growth will come from Chronic Cases, forecast to expand at a CAGR of 9.0% between 2026 and 2032. Chronic cases are the fastest-growing patient category, driven by the increasing prevalence of chronic diseases, which is expected to reach 50% by 2030. This trend indicates a rising need for ongoing thrombosis management among patients with recurrent issues. Healthcare providers must adapt their services to cater to the increasing number of chronic cases, ensuring continuous and effective thrombosis management.
By Delivery Setting – Inpatient Dominated, Cath Lab Expected to Grow Fastest
In 2025, Inpatient led the delivery setting split with a 41% share. Inpatient settings capture the largest share of the thrombosis treatment market as most procedures are performed in hospitals. These facilities are equipped with extensive resources, making them the primary choice for managing complex thrombosis cases effectively. Cath Lab is set to record the highest CAGR in this split, 8.6% over 2026–2032. Cath labs are the fastest-growing delivery setting for thrombosis treatment, attributed to their specialised focus on catheter-based interventions. This targeted approach allows for more efficient and effective procedures, making them increasingly attractive to healthcare providers. Investments in cath lab facilities and technologies will be essential for suppliers to address the increasing demand for specialised thrombosis treatments.
By End User – Hospitals Dominated, Surgical Centers Expected to Grow Fastest
Hospitals held a 42% share of the China Thrombosis Treatment Market by end user in 2025. Hospitals dominate the thrombosis treatment market as the primary providers of care, equipped to handle a broad spectrum of medical procedures. With over 2,500 certified hospitals in China, they play a vital role in delivering thrombosis treatment to a substantial patient population. Over 2026–2032, Surgical Centers are expected to post the fastest growth, at a CAGR of 8.4%. Surgical centers are the fastest-growing end users in the thrombosis treatment market, driven by a rise in surgical interventions for managing blood clots. Their specialised focus on surgical procedures enables them to effectively meet the increasing demand for targeted thrombosis treatments. Suppliers should explore partnerships with surgical centers to strengthen their market presence and cater to the growing demand for surgical thrombosis interventions.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- China Thrombosis Treatment Market Outlook
- Market Size of China Thrombosis Treatment Market, 2025
- Forecast of China Thrombosis Treatment Market, 2032
- Historical Data and Forecast of China Thrombosis Treatment Revenues & Volume for the Period 2022 - 2032F
- China Thrombosis Treatment Market Trend Evolution
- China Thrombosis Treatment Market Drivers and Challenges
- China Thrombosis Treatment Price Trends
- China Thrombosis Treatment Porter's Five Forces
- China Thrombosis Treatment Industry Life Cycle
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Treatment Type for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Pharmacologic Therapy for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Surgical Thrombectomy for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Catheter-Directed Therapy for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Combined Therapy for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Patient Category for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Adult Patients for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By High-Risk Cases for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Elderly Patients for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Chronic Cases for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Delivery Setting for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Inpatient for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Operation Theater for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Cath Lab for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Long-Term Care Units for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Surgical Centers for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Interventional Radiology for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Treatment Market Revenues & Volume By Multispecialty Clinics for the Period 2022 - 2032F
- China Thrombosis Treatment Import Export Trade Statistics
- Market Opportunity Assessment By Treatment Type
- Market Opportunity Assessment By Patient Category
- Market Opportunity Assessment By Delivery Setting
- Market Opportunity Assessment By End User
- China Thrombosis Treatment Top Companies Market Share
- China Thrombosis Treatment Competitive Benchmarking By Technical and Operational Parameters
- China Thrombosis Treatment Company Profiles
- China Thrombosis Treatment Key Strategic Recommendations
Market Covered
This report examines the market across the segments below.
By Treatment Type
- Pharmacologic Therapy
- Surgical Thrombectomy
- Catheter-Directed Therapy
- Combined Therapy
By Patient Category
- Adult Patients
- High-Risk Cases
- Elderly Patients
- Chronic Cases
By Delivery Setting
- Inpatient
- Operation Theater
- Cath Lab
- Long-Term Care Units
By End User
- Hospitals
- Surgical Centers
- Interventional Radiology
- Multispecialty Clinics
